The University of Oxford coronavirus vaccine produces a strong immune response in older adults, its latest trials have found.
The vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and people over 70.
Phase two data, published in The Lancet, suggests one of the groups most vulnerable to serious illness and death from Covid-19 could build immunity, researchers say.
According to the researchers, volunteers in the trial demonstrated similar immune responses across all three age groups (18-55, 56-69, and 70 and over).
The study of 560 healthy adults – including 240 over the age of 70 – found the vaccine is better tolerated in older people compared with younger adults.
The UK has 100 million doses of the Oxford jab on order, enough to vaccinate almost the entire population, pending regulatory approval.
The Oxford findings come after Pfizer and BioNTech announced that their vaccine candidate has shown 95% efficacy, with a 94% effectiveness in those aged 65 and over.
Forty million doses of that vaccine have been bought by the UK, with rollout potentially starting in early December if the jab is given the green light by regulators.